| May 28 |
Novartis and Clarius partner for psoriatic arthritis care in Canada
|
| May 27 |
Novartis (NVS) Presents Positive Data on Renal Drugs at ERA
|
| May 27 |
Novartis: Buy This Blue-Chip Dividend Stock On Sale Now
|
| May 27 |
Dr. Reddy’s and Novartis sign distribution agreement for anti-diabetes products
|
| May 27 |
Novartis’ atrasentan shows to reduce proteinuria in Phase III IgAN trial
|
| May 25 |
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
|
| May 25 |
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
|
